Electrocore Llc (ECOR)
NASDAQ:ECOR
ECOR Stock Chart & Stats
$5.86
$0.45(2.64%)
At close: 4:00 PM EST
$5.86
$0.45(2.64%)
Day’s Range― - ―
52-Week Range$4.16 - $8.64
Previous CloseN/A
Volume24.66K
Average Volume (3M)33.66K
Market Cap
$47.37M
Enterprise Value$49.74M
Total Cash (Recent Filing)$11.61M
Total Debt (Recent Filing)$9.40M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Apr 30, 2026EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding8,083,558
10 Day Avg. Volume29,982
30 Day Avg. Volume33,656
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)-22.29
Price to Sales (P/S)1.19
P/FCF Ratio-4.62
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue1.55
Enterprise Value/Gross Profit1.79
Enterprise Value/Ebitda-4.33
Forecast
1Y Price Target
$15.00Price Target Upside155.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$42.59M
Bulls Say, Bears Say
Bulls Say
Government Channel GrowthAnalyst attributes the company's revenue beat to strong momentum in the Veterans Affairs and Department of Defense channel and robust growth in the general wellness business, supporting increased adoption within federal health systems.
PTSD Clinical Trial And Indication ExpansionAnalyst notes that an ongoing clinical study testing the device for post‑traumatic stress disorder could enable an expanded regulatory indication and materially increase the addressable market if results are favorable.
Quell Acquisition And OTC OpportunityAnalyst points out that the acquired Quell Fibromyalgia business outperformed expectations and that integrating it into the Veterans Affairs network and launching an over‑the‑counter Quell product could meaningfully boost revenue.
Bears Say
Leadership Transition RiskAnalyst warns that the CEO retirement and interim leadership by the chief financial officer create management transition risk while the company searches for a permanent chief executive.
Liquidity Pressure From Cash BurnAnalyst highlights a declining cash balance and ongoing cash burn that could create liquidity pressure and limit execution of commercial and clinical plans.
Rising Expenses And Legal CostsAnalyst notes higher operating expenses, rising interest costs, and expected litigation fees that lowered the price target and increase pressure on profitability and valuation.
Electrocore News
ECOR FAQ
What was Electrocore Llc’s price range in the past 12 months?
Electrocore Llc lowest stock price was $4.16 and its highest was $8.64 in the past 12 months.
What is Electrocore Llc’s market cap?
Electrocore Llc’s market cap is $47.37M.
When is Electrocore Llc’s upcoming earnings report date?
Electrocore Llc’s upcoming earnings report date is Apr 30, 2026 which is in 32 days.
How were Electrocore Llc’s earnings last quarter?
Electrocore Llc released its earnings results on Mar 19, 2026. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.402 by $0.062.
Is Electrocore Llc overvalued?
According to Wall Street analysts Electrocore Llc’s price is currently Undervalued.
Does Electrocore Llc pay dividends?
Electrocore Llc does not currently pay dividends.
What is Electrocore Llc’s EPS estimate?
Electrocore Llc’s EPS estimate is -0.61.
How many shares outstanding does Electrocore Llc have?
Electrocore Llc has 8,083,558 shares outstanding.
What happened to Electrocore Llc’s price movement after its last earnings report?
Electrocore Llc reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.402. Following the earnings report the stock price went down -4.653%.
Which hedge fund is a major shareholder of Electrocore Llc?
Currently, no hedge funds are holding shares in ECOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Electrocore Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (155.97% Upside)
$15.00 (155.97% Upside)
Insider Transactions
Bought Shares
Worth $223.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.72%
12-Months-Change
Fundamentals
Return on Equity
-473.98%
Trailing 12-Months
Asset Growth
1.74%
Trailing 12-Months
Company Description
Electrocore Llc
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
ECOR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted strong top-line momentum — record Q4 revenue, double-digit annual growth (27% YoY), meaningful expansion in the general wellness channel (Truvaga +93% YoY) and early adoption in the VA/federal channel — along with strategic actions (leadership transition, experienced COO hire, Quell OTC launch) positioned to accelerate growth. Offsetting these positives are material operating cost increases, a wider GAAP net loss ($14.0M), modestly reduced cash balances (~$11.6M), nonrecurring other expenses, and limited near-term formal guidance due to the leadership transition. Overall, growth and commercial traction are clear, but profitability, expense control and liquidity remain important near-term challenges.View all ECOR earnings summariesECOR Stock 12 Month Forecast
Average Price Target
$15.00
▲(155.97% Upside)
Technical Analysis
Myomo
―
Modular Medical
―
NeuroOne Medical Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Ownership Overview
14.32% Insiders
3.22% Mutual Funds
3.62% Other Institutional Investors
76.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---